Very recently, preliminary results from a third demo evaluating ibrutinib compared to observation had been presented.one zero five Patients acquiring ibrutinib had a longer event-no cost survival, but no Over-all survival advantage, although the outcomes ended up even now immature. What's more, although severe adverse events rates ended up similar